NanoViricides, Inc. Calls for Shareholder Vote

TL;DR

NVIR is having a shareholder vote - big decisions ahead.

AI Summary

On December 7, 2024, NanoViricides, Inc. filed an 8-K report detailing a submission of matters to a vote of its security holders. The filing does not specify the exact nature of the vote or any associated proposals, but it indicates a formal process involving shareholder decisions is underway.

Why It Matters

This filing signals a significant corporate event where shareholders will have a say in the company's direction, potentially impacting future strategies and operations.

Risk Assessment

Risk Level: medium — Shareholder votes can lead to significant changes in company leadership or strategy, introducing uncertainty.

Key Players & Entities

• NanoViricides, Inc. (company) — Registrant
• December 7, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Shelton, Connecticut (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.00001 — h registered: Common Stock, par value $0.00001 per share NNVC NYSE -American Ite

Filing Documents

• tm2430926d1_8k.htm (8-K) — 33KB
• 0001104659-24-128066.txt ( ) — 201KB
• nnvc-20241207.xsd (EX-101.SCH) — 3KB
• nnvc-20241207_lab.xml (EX-101.LAB) — 33KB
• nnvc-20241207_pre.xml (EX-101.PRE) — 22KB
• tm2430926d1_8k_htm.xml (XML) — 3KB

07

Item 5.07. Submission of Matters to a Vote of Security Holders. On December 7, 2024, NanoViricides, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Meeting"). At the meeting, 6,096,059 shares of the Company's common stock and 883,177 shares of Series A Convertible Preferred Stock ("Series A Preferred Shares") entitled to vote at the Meeting, as of the record date of November 13, 2023, were present in person or by proxy, representing 47.1% of the Company's outstanding voting capital stock and constituting a quorum for the transaction of business. With a quorum present, the required shareholders approved the following proposals: (i) the re-election of Todd Rokita as a Class I Director and Makarand Jawadekar and Brian Zucker Class II Directors, each to a two-year term expiring at the 2026 annual meeting of stockholders and until their successor is duly elected and qualified or until their earlier resignation or removal; and (ii) the ratification of the appointment of EisnerAmper, LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2025. Each proposal is described in more detail in the Company's Proxy Statement filed with the Securities and Exchange Commission on October 15, 2024. The voting results of the shares of the Company's voting stock for each proposal are set forth below: Proposal – Election of Directors - Re-Election of Theodore Rokita as a Class I Director and Makarand Jawadekar and Brian Zucker as Class II Directors: Director For Against Broker Non-Votes Theodore E. Rokita 2,060,147 166,389 3,813,361 Makarand Jawadekar 1,951,381 272,416 3,813,361 Brian Zucker 2,088,483 139,413 3,813,361 Proposal 2 – Ratification of Accounting Firm – To ratify the appointment of EisnerAmper, LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2025: Votes For Votes Against Votes Abstained 5,757,913 230,937 107,209

SIGNATURES

SIGNATURES PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED. NANOVIRICIDES, INC. Date: December 12, 2024 By: /s/ Anil Diwan Name: Anil Diwan Title: Chairman, President

View Full Filing

View this 8-K filing on SEC EDGAR